Serological Analysis of Alpha-synuclein and NF-?B in Parkinson’s Disease Patients
Published: May 1, 2015 | DOI: https://doi.org/10.7860/JCDR/2015/.5978
Vineeta Gupta, Ravindra Kumar Garg , Sanjay Khattri
1. Senior Research Fellow, Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, India.
2. Professor and Head of Department, Department of Neurology, King George’s Medical University, Lucknow, Uttar Pradesh, India.
3. Professor, Department of Pharmacology & Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, India.
Correspondence
Dr. Vineeta Gupta,
Senior Research Fellow, Department of Pharmacology and Therapeutics, King George’s Medical University,
Lucknow-226003, Uttar Pradesh, India.
E-mail : vineeta16.gupta@gmail.com
Introduction: Several investigations have been made to determine the level of alpha-synuclein in the peripheral blood of Parkinson’s disease patients, but the results were very contradictory and inconclusive. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-?B) was also found to be involved in Parkinson’s disease, but there is a lack of studies investigating NF-?B in Parkinson’s disease patients. As far as our knowledge goes, no study reported the level of NF-?B in serum of Parkinson’s disease patients. In this context, present study was designed to make a baseline study in order to evaluate the levels of total alpha-synuclein and NF-?B in serum of Parkinson’s disease patients.
Materials and Methods: Serum samples were collected from Parkinson’s disease patients (n=97) and healthy controls (n=97). Their levels were determined by using Enzyme linked immunosorbent assay.
Results: The levels of total alpha-synuclein (patients=5.79±2.24 ng/ml, controls=6.20±1.61 ng/ml; p=0.14) and NF-?B (patients=1.38±0.99 ng/ml, controls=1.65±1.00 ng/ml; p=0.71) were lower in Parkinson’s disease patients than controls, but the differences were not statistically significant. This difference was also failed to reach significance between males (alpha-synuclein (p)=0.70, NF-?B (p)=0.84) and females (alpha-synuclein (p)=0.06, NF-?B (p)=0.77) in both the groups as well as within the groups. The levels of total alpha-synuclein and NF-?B were also not associated with Parkinson’s disease severity (alpha-synuclein (p) = 0.84, NF-?B (p) = 0.73).
Conclusion: A non-significant difference in the levels of total alpha-synuclein and NF-?B between Parkinson’s disease patients and controls suggested that these are not valuable biomarkers for Parkinson’s disease, more specifically in Indian population.
[
FULL TEXT ] | [ PDF]